Woodworth, Kate R;
Moulia, Danielle;
Collins, Jennifer P;
Hadler, Stephen C;
Jones, Jefferson M;
Reddy, Sujan C;
Chamberland, Mary;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Bell, Beth P;
Daley, Matthew F;
Mbaeyi, Sarah;
Dooling, Kathleen;
Oliver, Sara E.
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this includes m...
The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this includes m...
In 2021, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current recommendations on the use of tocolysis as published in the WHO recommendations on interventions to improve preterm birth outco...
In 2021, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current recommendations on the use of antenatal corticosteroids as published in the WHO recommendations on interventions to improve pre...
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...
Janus Kinase Inhibitors/therapeutic use,
COVID-19/drug therapy,
Antiviral Agents/therapeutic use,
Ivermectin/therapeutic use,
Hydroxychloroquine/therapeutic use,
Plasma/immunology,
Fluvoxamine/therapeutic use,
Colchicine/therapeutic use,
Immunization, Passive,
Receptors, Interleukin-6/therapeutic use,
Lopinavir/therapeutic use,
Adrenal Cortex Hormones/therapeutic use
The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is impor...
COVID-19/complications,
COVID-19/diagnosis,
Masks,
Global Health,
Hospitalization,
Respiration, Artificial,
Shock, Septic,
Breast Feeding,
Pregnancy,
Respiratory Distress Syndrome/etiology,
Pneumonia, Viral/etiology,
Palliative Care,
Rehabilitation,
Patient Care Management/organization & administration
El parto pretérmino en la región centroamericana tiene variaciones en cada país, así como
la mortalidad perinatal neonatal y materna que se deriva de la condición. La atención
adecuada sigue siendo una barrera en las zonas con más limitaciones en los servicios y el
personal sanitario disponible.
E...
Tocolytic Agents,
Obstetric Labor, Premature/diagnosis,
Obstetric Labor, Premature/prevention & control,
Peripartum Period,
Fetal Membranes, Premature Rupture/prevention & control,
Vulvovaginitis/prevention & control,
Vaginosis, Bacterial/prevention & control
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than a...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
